Clinical Trial Update: 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks [Phase 3]

View source ↗

Summary

Phase 3 parallel-group study comparing linagliptin plus pioglitazone at 5+15, 5+30 and 5+45 mg once daily against corresponding monotherapies, followed by compa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Actos (Pioglitazone)
• Tradjenta (Linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2014-04-21